IN8bio, Inc.
corporate_fare Company Profile
IN8bio, Inc. (NASDAQ:INAB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for INAB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 19 rated 8 or above. Recent SEC coverage for INAB spans 10-Q, 8-K, 424B5, SCHEDULE 13D/A.
Recent high-impact activity:
- Gamma-Delta T Cells Double Two-Year Survival in Glioblastoma, IN8bio Data Show
- IN8bio 10-Q: Going Concern Warning With $14.0M Cash Lasting Only Through April 2027
- IN8bio Q2 2026: Cash Only Through April 2027, Going Concern Warning Reiterated
- IN8bio's DeltEx DRI Doubles Progression-Free Survival in Glioblastoma, Published in JCO
- IN8bio's Glioblastoma Therapy Extends Survival to Over 19.5 Months, Nearly Doubling Standard of Care
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 15,733 shares in INAB as of the October 30, 2026 settlement, a 52.0% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 4.7% of INAB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for INAB, detected from its recent SEC filings · based on capital-structure filings through 2026-06-01.
At-The-Market Offering Launched · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →